Polymarket
Highest grossing movie in 2026?
Spider-Man: Brand New Day
AMC · NYSE
sell · 3 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 8, 2026 | Macquarie | Maintains | Neutral | $2.00 |
| May 7, 2026 | Citigroup | Maintains | Sell | $1.20 |
| February 26, 2026 | Macquarie | Maintains | Neutral | $1.50 |
| February 25, 2026 | Citigroup | Maintains | Sell | $1.10 |
| February 25, 2026 | Roth Capital | Maintains | Neutral | $1.50 |
| January 15, 2026 | Macquarie | Maintains | Neutral | $2.00 |
| January 12, 2026 | Citigroup | Maintains | Sell | $1.30 |
| November 13, 2025 | Citigroup | Maintains | Sell | $2.30 |
Live event probabilities associated with this company or market.
Polymarket
Spider-Man: Brand New Day
Recent debt restructuring and a $200 million registered direct offering signal proactive balance sheet management. Benchmark analyst Mike Hickey upgraded AMC to Buy with a $2.50 target, and Wedbush's Michael Pachter raised his target to $4, suggesting the company can navigate its debt load and move toward profitability.
AMC continues to report persistent net losses, negative shareholder equity, and negative cash flow. Citigroup's Jason Bazinet maintained a Sell rating, and the analyst consensus price target of $1.90 reflects deep skepticism that the company can overcome its high debt burden and achieve sustainable profitability.
Analysts point to a gradual box office recovery as a key catalyst, with Q2 FY26 revenue expectations of $1.46 billion — up from $1.4 billion a year prior. Benchmark's upgrade to Buy and Macquarie raising its target to $2 reflect growing confidence in sustained audience demand returning to theaters.
Structural competitive pressures from streaming platforms continue to threaten long-term theatrical demand. Roth Capital's Eric Handler cut his price target from $2 to $1.50, and Citigroup's ongoing Sell rating underscore concerns that the box office recovery remains fragile and insufficient to reverse AMC's fundamental challenges.
Medium- and long-term technical indicators are predominantly positive, with the 50-day, 100-day, 150-day, and 200-day moving averages all showing Buy signals. A pivot bottom buy signal issued in July 2025 produced a 15%+ gain, and the overall Barchart composite registers a 64% Buy rating.
Short-term technical indicators present a more cautious picture, with the 20-day moving average issuing a Sell signal and the Trend Seeker composite indicator on Hold. Danelfin's AI model assigns AMC a score of 4/10 with a negative probability advantage of -0.67% of outperforming the S&P 500 over the next three months.